News for Atai Life Sciences N.V. (ATAI)

On Tuesday, Cathie Wood-led Ark Invest executed significant trades, focusing on Bitmine Immersion Technologies Inc. (NYSE:BMNR) and Block Inc. (NYSE:XYZ).

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Read the full analysis on the stock here.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV ATAI fell sharply in pre-ma...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Celcuity Inc CELC rose sharply in pre-market trading after the company announced it will disclose the topline results of the PIK3CA Wild-Type Cohort f...

Atai Life Sciences drops 12% after a key schizophrenia drug misses a phase 2b trial primary endpoint. Read more here.

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpointInidascamine continues to exhibit a favorable safety and tolerability profileFull data set, including secondary endpoints and subgroup analyses will be forthcoming

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BOSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of Scott Braunstein, M.D., as Chairman of the Board. The company’s lead product candidate AGLE-102, a composite of mesenchymal stem cell derived extracellular vesicles (MSC-EVs), is currently being evaluated in a Phase 1/2a trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare pediatric skin blistering disorder.

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the 13 Best German Stocks to Invest in Now. On July 2, analysts at Canaccord Genuity lifted the stock’s price target from $11 to $12, while maintaining a Buy rating for its shares. The adjustment followed the joint announcement by Atai Life Sciences N.V. (NASDAQ:ATAI) and Beckley Psytech […]

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the 13 Best German Stocks to Invest in Now.

Atai Life Sciences (NASDAQ:ATAI) is one of the best-performing NASDAQ stocks according to analysts.

On July 2, 2025, Canaccord Genuity analyst Sumant Kulkarni announced a revision in the price target for ATAI Life Sciences (ATAI), raising it from $11.00 to $12

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Tesla Inc. and Coinbase Global Inc. . These trades reflect Ark’s strategic positioning amid ongoing market developments.

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling over 150 points on Tuesday. The Dow traded up 1.03% to 44,549.24 while the N...

U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday. Shares of Mesoblast Limited MESO rose sharply during Tuesday's session aft...

Mebufotenin benzoate also requires a much shorter period of clinical supervision in trial

U.S. equity futures are trending lower early Tuesday, July 1, 2025, as markets kick off the second half of the year with a cautious tone following an